AI-Driven CRISPR Design: Methods, Tools, Applications and Challenges

1. Introduction

1.1. Overview of CRISPR Systems

First identified in 1987 as atypical repetitive sequences in Escherichia coli, CRISPR-Cas systems were subsequently characterized as adaptive immune mechanisms in bacteria and archaea [1], heralding a new era in gene-editing technology. Following the identification and nomenclature of Cas genes in 2002 [2], the field progressed rapidly from mechanistic elucidation to engineering applications. Key milestones included the revelation of the homology between spacer sequences and phage or plasmid DNA in 2005 [3] and the experimental validation of CRISPR-mediated adaptive immunity in 2007 [4]. Notably, the repurposing of CRISPR-Cas9 in 2012 marked a pivotal transition from fundamental research to practical application [5].

Mediated by RNA-guided DNA recognition and cleavage, CRISPR-Cas systems facilitate genome editing with unprecedented precision. The available toolkit has evolved significantly from initial double-strand break (DSB)–dependent methods to encompass diverse editing modalities. Conventional Cas nucleases induce DSBs, relying on cellular repair pathways—specifically non-homologous end joining (NHEJ) or homology-directed repair (HDR)—to effectuate gene knockouts or insertions, thereby underpinning functional genomics and therapeutic strategies. However, because DSBs can result in unpredictable repair outcomes and genomic instability, there has been a drive toward higher-fidelity strategies [6,7]. Base editors (BEs) address the challenge of single-nucleotide editing by fusing a Cas9 nickase with deaminases, enabling C→T or A→G conversions without generating DSBss [8,9]. Prime editors (PEs) further expand the editing repertoire by combining a Cas9 nickase with reverse transcriptase; utilizing a prime-editing guide RNA (pegRNA) as a template, they achieve precise insertions, deletions, and substitutions in a DSB-independent manner [10]. Additionally, epigenetic editors (EEs) fuse catalytically dead Cas9 (dCas9) with epigenetic modifiers to modulate gene expression, offering robust tools for epigenetic research [11,12,13].

Figure 1. Gene-editing modalities. Major CRISPR editing modes: Cas nuclease, base editor, prime editor, and epigenetic editor.

Figure 1. Gene-editing modalities. Major CRISPR editing modes: Cas nuclease, base editor, prime editor, and epigenetic editor.

1.2. Challenges in CRISPR Design and Opportunities for AI

Despite their transformative potential, the practical application of CRISPR technologies encounters significant hurdles. Traditional design paradigms, often predicated on empirical heuristics and trial-and-error [14,15], are inherently inefficient, resource-intensive, and time-consuming. The design of single-guide RNAs (sgRNAs) necessitates a delicate balance among on-target efficiency, off-target risks, editing window positioning, and protospacer adjacent motif (PAM) constraints [16,17,18]. Similarly, engineering Cas proteins requires profound structure–function insights; however, conventional methodologies struggle to systematically navigate the vast sequence space [19,20,21]. Delivery optimization presents comparable complexities, involving intricate trade-offs among lipid nanoparticle (LNP) formulations, mRNA structural integrity, and tissue specificity [22,23,24].

As experimental scales and complexities expand, traditional methods prove inadequate for high-throughput design requirements [25]. Furthermore, clinical translation imposes rigorous standards for efficiency, specificity, and safety, necessitating robust multi-objective optimization [26,27]. This complexity delineates a critical niche for artificial intelligence (AI). It is important to note, however, that for straightforward targets, scenarios demanding high interpretability, or cases with extremely scarce labeled data, rule- and experience-based designs remain prevalent [28,29]. Consequently, AI does not wholly supplant traditional methods; rather, the two approaches often function synergistically [17,30,31].

Machine learning (ML) and deep learning (DL) excel at processing high-dimensional data, deciphering complex patterns, and executing multi-objective optimization. Within the context of CRISPR design, AI algorithms can elucidate the relationships between sgRNA efficiency and sequence features by mining large-scale experimental datasets [28,29], accurately predict off-target sites [30], optimize Cas protein structure and function [32,33], and even facilitate the de novo design of novel editing systems [34,35]. Moreover, generative models—such as diffusion models and variational autoencoders—offer innovative avenues for exploring sequence and structural landscapes. These computational approaches promise to accelerate the design cycle while enhancing success rates and predictability.

1.3. Aims and Organization of This Review

This review provides a comprehensive survey of AI-driven tools and methodologies for CRISPR system design, with a specific emphasis on applications spanning sgRNA design, off-target prediction, Cas protein engineering, delivery optimization, and gene-editing experimental planning. To ensure conceptual clarity, we distinguish between methods—defined here as algorithmic and modeling paradigms (e.g., supervised learning, deep learning)—and tools, which refer to the software, platforms, or databases that implement them. The mapping between these two categories is detailed in Section 4 and Section 5.

Figure 3. Evolution of CRISPR design tools. Progression from the foundational (1987–2015) and computational-aided (2014–2021) phases to the AI-driven phase (2017–present), with representative tools, milestones, and technical features aligned to the toolkit classification in Table 2.

Figure 3. Evolution of CRISPR design tools. Progression from the foundational (1987–2015) and computational-aided (2014–2021) phases to the AI-driven phase (2017–present), with representative tools, milestones, and technical features aligned to the toolkit classification in Table 2.

Reader Guide and Search Scope:

For an in-depth analysis of methodologies and algorithmic organization, please refer to Section 4 and Figure 4. For guidance on tool selection and functional taxonomy, see Section 5 (specifically Section 5.9) and Table 2. Clinical applications and case studies are discussed in Section 6, while Section 7 addresses current challenges and future outlooks. The literature and tools surveyed herein were identified through PubMed, Web of Science, Google Scholar, and bioRxiv using keywords such as CRISPR, artificial intelligence, sgRNA design, off-target prediction, and gene editing, covering publications through February 2026.

Scope of Coverage:

This review synthesizes five families of AI methods and eight categories of tools (encompassing dozens of representative examples listed in Table 2), highlighting their utility in therapy, agriculture, and basic research. For task-oriented navigation:

• sgRNA Design and Scoring: See Section 4 (Figure 4) and Section 5 (C1d, 5.9).
• Off-target Prediction: See Section 5 (C1e) and Table 2.
• Cas Structure Prediction and Generation: See Sections C2, C4, and C5.
• Delivery and Experiment Planning: See Sections C6 and C8.

2. Technical Pipeline for AI-Driven CRISPR System Design

AI-driven CRISPR design follows a multi-stage, iteratively refined closed loop. Given an editing objective—target gene, site(s), and desired edit type—the workflow typically comprises four stages: component design, functional prediction, scheme optimization, and experimental validation.

Component design encompasses delivery systems, RNA sequences, and Cas proteins. Delivery design includes optimization of LNP or adeno-associated virus (AAV) vectors with respect to encapsulation efficiency, tissue specificity, and immunogenicity. RNA design covers mRNA and guide RNA (gRNA) optimization for stability, translation efficiency, and targeting specificity. Cas acquisition and optimization proceed along three paths: (i) AI-driven discovery of novel Cas systems using protein language models such as ESM [36]) and deep learning on metagenomic data; (ii) selection of known Cas variants from existing libraries according to PAM range, efficiency, and specificity; (iii) engineering of Cas via AI-assisted [32] protein design to extend PAM recognition, improve efficiency, or reduce size for delivery.

Functional prediction is where AI is central. Deep learning, graph neural networks, and related models predict sgRNA on-target efficiency, off-target risk, protein structural stability, and editing and repair outcomes [37,38], informing downstream optimization.

Scheme optimization uses predictions to tune parameters and components for specific editor types (BE, PE, EE), balancing efficiency, specificity, and safety—e.g., sgRNA adjustment, Cas variant choice, and editing window selection.

Experimental validation employs wet-lab methods such as GUIDE-seq [39] and CHANGE-seq [40] and AI-assisted analysis. Validation data feed model training and parameter updates, closing the loop. This data-driven iteration improves success rates and predictability and enables more systematic exploration of design space than rule-only approaches.

3. Evolution of CRISPR Design Tools

CRISPR design tools have evolved from foundational discovery [1,34] through computational assistance to AI-driven design. Chronologically and technically, three phases are distinguished: foundations (1987–2015), computational-aided design (2014–2021) [17], and AI-driven design (2017–present) [28], with 2017–2021 as an overlapping transition in which deep learning gained prominence alongside rule-based tools.

3.1. Foundational Phase (1987–2015)

Understanding CRISPR-Cas rested on nearly three decades of basic research. In 1987, Japanese researchers first observed unusual repeats in the E. coli genome [1]; the finding received limited attention but laid groundwork. In 2002, Cas genes were identified and named, linking repeats to Cas proteins [2]. In 2005, spacer–phage/plasmid DNA matches implied a role in adaptive immunity [3]. In 2007, CRISPR was shown experimentally to provide adaptive immunity by recognizing and clearing foreign DNA—a milestone for later applications [4].

In 2010, the Cascade complex (type I-E) clarified how multi-protein assemblies recognize and cleave DNA [41]. In 2012, engineered CRISPR-Cas9 began the modern gene-editing era [5]. The same year, Cpf1 [15] (later Cas12a) and Cas13 [42] broadened the toolkit—Cas12a with distinct PAM requirements and Cas13 for RNA targeting. In 2015, anti-CRISPR proteins revealed regulatory mechanisms and tools for temporal control of editing [43,44].

During this phase, effort focused on mechanism; design tools were not systematized and relied on experience and simple sequence rules [45].

3.2. Computational-Aided Phase (2014–2021)

As CRISPR spread, systematic computational tools for sgRNA design and analysis became essential. In 2014, early sgRNA tools appeared; CHOPCHOP v1 [46] marked the start of computational-aided design. MAGECK [47] and related tools enabled pooled CRISPR screen analysis. In 2015, GUIDE-seq [39] and similar methods linked experiments to predictive models and supplied high-quality training data. CRISPRscan [48] systematized rule-based scoring. From 2016 to 2017, Azimuth and CFD (cutting frequency determination) [17]standardized efficiency scoring; CRISPResso [49] standardized outcome analysis; CRISPOR [50,51] integrated multiple tools into a one-stop platform.

From 2020 to 2021, tools targeted specific editors: PrimeDesign [51] and BE-Hive [52] for prime and base editors; CHANGE-seq [40] expanded off-target data; SpG and SpRY [53] approached PAM-free targeting; CRISPick [54,55] standardized library design. This phase emphasized standardization and rule-based or shallow machine learning, setting the stage for AI-driven design.

3.3. AI-Driven Phase (2017–Present)

Transformers [56] in 2017 marked growing AI use in CRISPR design; attention mechanisms capture long-range sequence dependencies relevant to sgRNA efficiency.

From 2018 to 2020, deep learning advanced across tasks. DeepCRISPR [28] and DeepSpCas9 [57] demonstrated strong Cas9 sgRNA efficiency prediction from large datasets; tools diverged by effector—e.g., DeepCpf1 [57] for Cas12a and TIGER [58] for Cas13d alongside Cas9-oriented tools such as CRISPOR [50,51] (Table 2, C1d). Deep learning also improved off-target prediction [59].

Since 2021, generative AI and foundation models have created new opportunities. AlphaFold2 [33] and AlphaFold3 [60] enable accurate Cas structure prediction for engineering. Protein language models such as ESM [36] improve sequence representation and function prediction. Diffusion models [35] support de novo protein and variant design, shifting emphasis from prediction alone to generative design [34].

Current trends include multimodal integration, end-to-end pipelines, and automation—together indicating a growing role for AI in CRISPR system design [61].

4. AI Algorithms and Models in CRISPR Applications

AI toolkits have substantially reshaped protein and CRISPR system design. This section focuses on deep-learning–driven tools that infer sequence–structure–function relationships from data and capture patterns that traditional feature engineering often misses. Rule-based or shallow machine-learning tools such as Rule-set 2 [17] are noted but not emphasized. Deep learning here comprises two pillars (Figure 4): learning paradigms (left column)—how models learn sequence–structure–function mappings; model architectures (middle column)—how geometric and biological priors encode biophysical complexity. Together they support CRISPR tasks (right column, C1–C8). Section 4.1 and Section 4.2 summarize paradigms and architectures; representative methods and tools appear in Section 5 and Table 2.

4.1. Learning Paradigms

Generalizing patterns from large protein and sequence databases is central to intelligent CRISPR design; models typically implement one of three paradigms—supervised, unsupervised, or reinforcement learning (Figure 4, left column).

L1. Supervised learning trains models on labeled input–output pairs (Figure 4, L1).

Standard supervision. CRISPR AI tools often use assay-labeled data: sequence–function predictors take protein or sgRNA sequence as input and activity or efficiency as output (e.g., Rule Set 2 [17]); structure predictors such as AlphaFold2 [33] take sequence and PDB structures as labels. Deep learning and attention models (CNN [59], RNN [62], Transformer [56], DNABERT [63]) belong here and support end-to-end off-target prediction such as DeepCRISPR [28], Indel/repair outcome prediction, base-editor efficiency and window prediction [52], and multitask models integrating chromatin and cross–cell-type gRNA efficiency.

Label-efficient supervision. When labels are scarce or costly, transfer learning[65], zero-/few-shot learning [62], and active learning can improve data efficiency—relevant when CRISPR training data are limited [65].

L2. Unsupervised learning learns patterns from unlabeled data to obtain useful representations (Figure 4, L2). Common themes include the following (not exhaustive).

Language models use next-token prediction or masked language modeling (MLM); the former generates sequence stepwise [66], the latter infers masked tokens from context. Protein and nucleic acid language models (ESM [36], ProGen [67], DNABERT [63]) support Cas representation, function prediction, and sequence generation in CRISPR contexts.

Diffusion models learn a reverse noising process to recover structure or sequence [68]; training on unlabeled PDB structures, for example, enables unconditional or conditional generation of physically plausible proteins for Cas and editor design [69].

Variational autoencoders (VAEs) encode data into a distribution with a prior (often Gaussian) [70]; VQ-VAE uses discrete codes [71]. Together with diffusion and GANs [72], VAEs support exploration of sequence space for Cas design [73].

Contrastive learning distinguishes positive pairs from negatives (e.g., crops from the same protein image as positives) [74], aiding representation and multimodal alignment [75].

L3. Reinforcement learning (RL) learns long-horizon policies via environment interaction, reward [76], and state transitions (Figure 4, L3). Components may include:Policy: maps states to actions (stochastic).Value function: estimates expected return from a state.Model: predicts next state and reward for planning.

In protein design, EvoPlay [77] treats sequence as state and point mutations as actions; surrogate models (e.g., AlphaFold2 [33]) can approximate assay rewards. The agent combines policy, value, and sequence–function models to optimize predicted reward [78,79]. In CRISPR, RL suits gRNA library design, protocol optimization, and ordering of targets in multi-gene editing, but reward specification and sample complexity remain challenging [80].

The relationships and flows among paradigms, architectures, and CRISPR tasks are summarized in Figure 4; tools and examples appear in Section 5 and Table 2.

4.2. Model Architectures

Beyond learning paradigms, model architecture encodes geometric and biological priors so that predictions respect intrinsic constraints (Figure 4, middle column) [81]. For example, rigid motions of a protein should not change biological behavior—geometric priors are built into the architecture [33]; biological priors (residue interactions, folding principles) encourage physically plausible outputs [82]. Without such priors, models may overfit superficial patterns and generalize poorly. Architectures are chosen for sequences, graphs, or 3D structure [83,84]; CRISPR-related tools often combine several [85]. Below we briefly summarize common architectures for protein and nucleic acid modeling.

M1. Convolutional neural networks (CNNs) detect local spatial patterns with approximate translation invariance [86] (Figure 4, M1). In vision and 1D sequence tasks they extract local motifs and window features [87]; in CRISPR they support sgRNA efficiency, editing windows, and end-to-end off-target prediction.

M2. Recurrent neural networks (RNNs) and LSTMs process sequences token by token while retaining memory of past tokens [89] (Figure 4, M2), suiting early sequence-to-function modeling.In protein bioinformatics they are employed to predict secondary structure and subcellular localization [90]; in genomics they capture long-range dependencies and regulatory motifs [91], such as the hybrid DanQ model for quantifying the function of DNA sequences.

M3. Transformers use self-attention to relate all token pairs in parallel rather than strictly left-to-right [57], improving long-range dependency modeling and coupling sequence termini (Figure 4, M3). In CRISPR they are widely used for gRNA/pegRNA efficiency, joint on/off-target prediction, and multitask models (e.g., DNABERT [63], TIGER [59], CRISP-RCNN [92], TransLNP [93]).

M4. Graph neural networks (GNNs) represent entities as nodes and relations as edges [94], where proteins are often modeled as contact graphs with residues as nodes [95] (Figure 4, M4). They support molecular property prediction [96], LNP lipid discovery [97], and protein–complex interface modeling [98] (Table 2: C2/C3/C6).

M5. Geometric and 3D networks operate on three-dimensional structure with explicit rotation and translation invariance [82], yielding orientation-independent predictions (Figure 4, M5). They underpin structure prediction and design (e.g., AlphaFold2/3 [33,61] , RFDiffusion [35], RF-AllAtom [99]) for Cas modeling and de novo design (Section 5: C2/C5).

In practice, researchers first choose a learning paradigm: interpretability or limited labels favor supervised learning (L1) and classical feature models [100]; exploration or de novo generation favors unsupervised and generative models (L2) or RL (L3) [101]. Architecture choice follows data type and compute [102]: long, context-sensitive tasks often use Transformers (M3); local motif and efficiency tasks often use CNNs (M1); molecules and complexes may use GNNs (M4) or geometric networks (M5). Mappings to specific tools appear in Section 5 and Table 2.

5. CRISPR Toolkit Classification and Applications

The AI-driven CRISPR toolkit has evolved from simple sequence-matching algorithms to complex generative systems. Based on the technical pipeline (Figure 2) and the mapping of learning paradigms (Figure 4), these tools are categorized into four functional clusters that bridge the gap between in silico design and experimental execution.

In this section, we categorize AI-driven CRISPR tools into eight functional modules (C1–C8), following the logical workflow of genome editing. A comprehensive summary of these tools, including their specific tasks, algorithmic foundations, and primary references, is provided in Table 2.

5.1. CRISPR-Cas Database Search and Component Identification(C1)

The primary challenge in CRISPR design is balancing on-target efficiency with genomic specificity. AI has redefined this stage by transitioning from rule-based heuristics to multi-dimensional, context-aware models.

• Component Discovery and PAM Characterization: Tools like CRISPRCasFinder [103] and Protein2PAM [107] have automated the identification of novel Cas systems and their PAM requirements from metagenomic data. By leveraging protein language models (PLMs), these tools can predict the targeting range of uncharacterized orthologs, significantly expanding the targetable genome.
• On-target Efficiency Prediction: Modern design platforms, such as DeepCRISPR [28] and TIGER [59], utilize CNNs and Transformers to capture complex sequence-activity relationships. Unlike early tools, these models integrate “contextual” features—including chromatin accessibility, DNA torsion, and epigenetic marks—to provide high-precision scoring for Cas9, Cas12a, and Cas13d systems.
• Specificity and Off-target Assessment: To mitigate the risk of unintended mutations, AI-driven specificity tools have moved beyond simple mismatch counting. Models like Elevation [30] and Cas-Offinder [109] employ machine learning to predict off-target landscapes across the entire genome. These computational predictions are increasingly integrated with high-throughput experimental data from assays such as GUIDE-seq [39] and CHANGE-seq [40], enabling a more rigorous safety profile for therapeutic applications.

5.2. Structural Elucidation and Functional Mapping (C2–C3)

Understanding the Cas-gRNA-DNA ternary complex is the prerequisite for rational engineering. AI has transformed this field from static crystallography to a multi-scale predictive pipeline, moving from individual components to functional ensembles.

• From Monomer Folding to Rapid Inference: The foundation of CRISPR structural modeling lies in predicting the three-dimensional fold of novel Cas proteins from their primary sequences. While AlphaFold2 [33] set the benchmark for atomic accuracy, protein language models like ESMFold [36] have enabled the structural annotation of millions of metagenomic Cas orthologs at unprecedented speeds, facilitating the discovery of compact and thermostable variants.
• Multi-entity Cofolding and RNP Assembly: The functional unit of CRISPR is the ribonucleoprotein (RNP) complex. The current “all-atom” frontier, led by AlphaFold3 [61] and RoseTTAFold All-Atom [99], allows for the simultaneous co-folding of proteins, gRNA, and target DNA. These models accurately position essential metal-ion cofactors (e.g., Mg2+) and small-molecule ligands, providing a “cleavage-competent” snapshot that is vital for designing chimeric editors like Base and Prime editors.
• Functional Hotspots and Regulatory Mapping: Beyond static scaffolds, geometric deep learning tools such as NucleicNet [122] and Metal3D [125] map the “hotspots” of molecular interaction. These models pinpoint DNA-binding interfaces and catalytic centers, enabling the rational design of high-fidelity mutants. Furthermore, AI predictors for post-translational modifications (PTMs), such as DeepMVP [127] and MusiteDeep [128], identify regulatory sites that govern Cas stability and nuclear localization in eukaryotic cells, offering a roadmap for optimizing editor performance in vivo.

5.3. Generative Synthesis and De Novo Design (C4–C5)

The most significant paradigm shift in CRISPR engineering is the move from predicting existing systems to generating novel, synthetic effectors [34]. This generative frontier explores a sequence-structure space far beyond natural evolution.

• Evolution-Guided Sequence Generation: Protein language models (PLMs) such as ESM-3 [133] and ProGen [129,130] treat amino acid sequences as a biological language, learning the underlying “grammar” of protein fitness. By sampling from these learned distributions, researchers can generate synthetic nucleases that maintain high functional activity while remaining evolutionarily distant from natural Cas9. Advanced genomic models like Evo [131,132] further extend this by co-designing the Cas protein alongside its associated non-coding RNA (gRNA) arrays.
• De Novo Structural Scaffolding: Diffusion-based models, led by RFDiffusion [138] and Chroma [139], have revolutionized the design of protein backbones from scratch. These tools can generate diverse and programmable architectures tailored to specific DNA targets. The recent advancement of RFDiffusionAA (All-Atom) [99] allows for the de novo design of protein pockets specifically coordinated around gRNA and metal-ion cofactors, enabling the creation of miniaturized or hyper-specific editors.
• Inverse Folding and Sequence-Structure Co-design: To bridge the gap between a designed 3D scaffold and a realizable sequence, “inverse folding” tools like ProteinMPNN [32], and LigandMPNN [135] identify amino acid sequences that fold into the target geometry with high stability. Integrated pipelines now support the simultaneous optimization of both sequence and structure, ensuring that the generated editors are physically stable and energetically favorable for ribonucleoprotein (RNP) assembly.

5.4. Developability Screening and Agentic Orchestration (C6–C8)

The final stage of the technical pipeline addresses the “delivery gap” and the complexity of experimental execution, ensuring that in silico designs translate effectively into in vivo outcomes.

• Virtual Screening for Function and Delivery: Before physical synthesis, candidates undergo multi-objective screening. Tools like EVOLVEpro [144] and AiCE [143] predict the functional impact of mutations on editing efficiency. Simultaneously, developability predictors such as LNP_ML [146] and COMET [147] navigate the vast chemical space of ionizable lipids to optimize mRNA delivery vehicles. For AAV-mediated delivery, Bryant et al. [152] utilized deep learning to design over 110,000 functional AAV2 capsid variants.
• Nucleic Acid Synthesis and Stability Optimization: To ensure robust expression of the editing machinery, DNA/RNA sequences must be optimized for synthesis and translation. LinearDesign [151] utilizes computational linguistics algorithms to identify mRNA sequences with optimal codon usage and high structural stability (Minimum Free Energy). This co-optimization significantly extends the half-life of the mRNA cargo, which is a critical factor for high-efficiency LNP-mediated delivery.
• Agentic Orchestration of Gene-Editing Experiments: The integration of the entire design-to-validation workflow is now facilitated by agentic frameworks like CRISPR-GPT [62]. By leveraging large language models (LLMs) and specialized toolkits (C1–C7), these systems can map natural-language biological goals into structured, multi-step experimental plans. This end-to-end orchestration reduces human error and democratizes access to complex genome engineering by providing automated guidance from target selection to protocol execution.

5.5. Current Bottlenecks

Despite these advances, critical challenges remain: (1) Data Bias: Most C1 tools are biased toward mammalian data, limiting generalization to non-model species. (2) Dynamics: Static models struggle to capture the conformational plasticity essential for the Cas catalytic cycle. (3) Validation: Generative models still produce “biological hallucinations,” necessitating extensive wet-lab validation to filter non-functional variants.

6. Case Studies: Quantifying the AI-Driven Paradigm Shift

The integration of AI into CRISPR workflows has fundamentally transitioned genome editing from stochastic discovery to deterministic engineering. This section analyzes three landmark cases where computational frameworks resolved long-standing bottlenecks in nuclease potency, vector capacity, and systemic delivery.

6.1. Generative Design of Novel Nucleases: The OpenCRISPR-1 Framework

Natural CRISPR-Cas systems are constrained by the evolutionary trajectories of their host prokaryotes. Ruffolo et al. [34] circumvented these biological limits by employing a Protein Language Model (PLM)-centric pipeline to design OpenCRISPR-1, a high-performance de novo editor.

• Computational Innovation: By operating in a latent sequence space, the generative model explored a landscape ~ 4.8-fold more diverse than extant metagenomic databases. This allowed for the identification of functional motifs that are evolutionarily distant from wild-type SpCas9.
• Performance Benchmarking: OpenCRISPR-1 incorporates ~ 400 mutations relative to its nearest natural orthologs. Despite this high structural divergence, it achieved a 95% reduction in off-target activity (0.32% vs. 6.1% for SpCas9) while maintaining a robust on-target indel rate of 56%.
• Bioinformatics Significance: This case demonstrates that PLMs can “hard-code” high fidelity into the primary sequence, bypassing the need for labor-intensive, iterative rational design or directed evolution.

6.2. Structure-Informed Optimization: Engineering Compact Fanzor Systems

The clinical utility of CRISPR is often restricted by the <4.7 kb cargo capacity of Adeno-Associated Virus (AAV) vectors. While eukaryotic Fanzor (Fz) proteins are naturally compact, their innate editing efficiency in mammalian cells is suboptimal. Li et al. [153] utilized AlphaFold3 and the EVOLVEpro framework to bridge this fitness gap.

• Structure-to-Function Mapping: By leveraging high-resolution structural predictions of the ribonucleoprotein (RNP) complex, the AI-guided evolution loop identified critical residues for stabilizing the ωRNA-DNA interface.
• Quantified Improvements: The resulting MmeFz2–ωRNA system exhibited a 32-fold mean increase in editing activity across 38 endogenous loci. Furthermore, AI-driven truncation reduced the ωRNA size by 30% while simultaneously enhancing total system activity by 20-fold.
• Translational Impact: This optimization enables the entire editing machinery to be packaged within a single AAV vector, resolving the efficiency loss and complex stoichiometry associated with dual-vector delivery systems.

6.3. Predictive Modeling for Delivery: Virtual Screening of Ionizable Lipids

The chemical space for ionizable lipids—the critical component of Lipid Nanoparticles (LNPs)—is astronomically large (>10¹⁰ combinations), rendering exhaustive physical screening computationally and experimentally intractable. Li et al. [154] integrated combinatorial chemistry with supervised machine learning to navigate this space.

• Algorithmic Efficiency: The team performed a virtual screen of ~ 40,000 candidates, but the high predictive power of the model allowed them to synthesize only 16 top-tier leads (0.04% of the virtual library).
• Validation & Hit Rate: The model achieved a 100% functional success rate in experimental assays. The lead lipid (119-23) demonstrated superior tissue-specific mRNA delivery compared to current industry standards (e.g., MC3 or SM-102).
• R&D Acceleration: This data-driven approach compressed the discovery timeline from the traditional 18–24 months to less than 6 months, illustrating how predictive modeling can “de-risk” the development of CRISPR delivery vehicles.

7. Challenges and Future Directions

7.1. Current Challenges

AI performance depends on data quality and quantity; CRISPR applications suffer from scarce high-quality labels, noisy high-throughput data, limited cross-experiment standardization, and modest cross-cell-type and cross-species generalization. Deep models are often opaque, complicating mechanism insight and regulatory review. Clinical translation demands experimental validation of predictions—costly and slow—with frequent prediction–experiment gaps. Ethics and regulation (e.g., germline editing, enhancement) and jurisdictional differences require robust safety assessment including off-target analysis.

7.2. Outlook

Progress will likely emphasize multimodal integration (sequence, structure, chromatin accessibility, histone marks, single-cell expression), real-time optimization (predict → validate → update models; online learning), and personalized design (patient genotype, cell type, tissue context). Research priorities include Cas engineering (PAM expansion, efficiency, specificity, miniaturization), improved off-target prediction, and smarter LNP/AAV design. Gaps remain for dedicated AI tools for prime and epigenetic editors, single-cell editing heterogeneity, and harmonized regulatory evidence standards. Interdisciplinary collaboration, data sharing, and ethical frameworks will be needed to translate AI-driven CRISPR safely from bench to clinic.

8. Limitations of This Review

Our literature and tool selection have limitations: search strategy (databases, keywords, time window) is summarized in Section 1.3 and may omit some recent work; taxonomy and representative tools involve subjective choices, and generative and RL tools evolve rapidly—readers should consult official documentation and primary literature. We do not comprehensively treat ethics and regulation beyond brief notes. Tool and dataset access: official sites or appendices as required by the target journal. Competing interests: The authors declare no competing interests.

9. Conclusion

AI contributions to CRISPR design can be summarized in three phases: 2014–2017 computational standardization and integration; 2017–2020 deep learning breakthroughs in sgRNA efficiency and off-target prediction; and from 2021 generative AI and foundation models enabling a shift from prediction to design. Five AI method families and eight tool categories span design through validation and experiment planning, with concrete applications in genetic disease, cancer, crops, and functional genomics. Challenges include data quality and generalization, interpretability, validation, and ethics; multimodal AI, real-time optimization, and personalized design are promising directions. Continued collaboration and governance will be essential to realize safe, effective translation. Deep integration of AI and CRISPR is reshaping discovery and development from target identification through clinical development and merits sustained attention from academia and industry.

Key Points

· Overview of artificial intelligence methods applied in CRISPR design.

· Evaluation of current computational tools for CRISPR-Cas systems.

· Discussion of diverse applications of AI-driven CRISPR technologies.

· Identification of critical computational challenges and future directions.